Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.5 USD | +0.16% | +6.24% | +51.22% |
May. 03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
May. 02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.22% | 2.36B | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Credit Suisse Downgrades Kymera Therapeutics to Neutral From Outperform, Notes 'Too Much Risk' in Recent Readout for KT-474's Part C; Lowers PT to $32 From $47